ライフサイエンスコーパス: glycoprotein Ib

1 lack of interaction between huVWF and murine glycoprotein Ib.

2 as integrins or the von Willebrand receptor glycoprotein Ib.

3 platelet binding, which depended on platelet glycoprotein Ib.

4 tease-activated receptor 1 (PAR1), PAR4, and glycoprotein Ib.

5 raction with a peptide derived from platelet glycoprotein Ib.

6 y of a noncatalytic interaction site such as glycoprotein Ib.

7 that mediates vWF interaction with platelet glycoprotein Ib.

8 the two other thrombin receptors, PAR-3 and glycoprotein Ib.

9 sible for binding the platelet vWF receptor, glycoprotein Ib.

10 (RGD) sequence in the C-terminus of vWF, and glycoprotein Ib alpha (GP Ib alpha), which interacts wit

11 Interaction of glycoprotein Ib alpha (GPIb alpha) with von Willebrand f

12 Glycoprotein Ib alpha (GpIbalpha), a trans-membrane glyc

13 ough interactions with the platelet receptor glycoprotein Ib alpha (GPIbalpha).

14 In contrast, glycoprotein Ib alpha binding to immobilized von Willebr

15 which then becomes damaged by apoptosis and glycoprotein Ib alpha chain (CD42b) shedding.

16 that the loop to beta-hairpin transition in glycoprotein Ib alpha is induced by flow before binding

17 Binding of the A1 domain in VWF to the glycoprotein Ib alpha subunit (GPIbalpha) on the surface

18 rface translocation mediated by the membrane glycoprotein Ib alpha.

19 t neither von Willebrand factor nor platelet glycoprotein Ib-alpha receptor (GPIb-alpha) is required

20 d III but also decreased binding to platelet glycoproteins Ib and IIbIIIa.

21 es and platelets, where, in association with glycoprotein Ib beta, glycoprotein V, and glycoprotein I

22 lytically inactive FPR-thrombin, which binds glycoprotein Ib but does not inhibit rPAR1(T) cleavage,

23 Mutations in VWF or platelet glycoprotein Ib can either reduce or increase the affini

24 tegrin alpha2beta1, glycoprotein VI, and the glycoprotein Ib complex, represent unexploited targets o

25 3OWKQ (G --> V)233V234 in the alpha chain of glycoprotein Ib (GPIb alpha).

26 actor (pvWF) has been shown to bind to human glycoprotein Ib (GPIb) and cause activation of human (or

27 The individual contributions of glycoprotein Ib (GPIb) and the seven transmembrane domai

28 esence of ITP plasma containing antiplatelet glycoprotein Ib (GPIb) autoantibodies (P <.001) as compa

29 sites that are involved in downregulation of glycoprotein Ib (GpIb) binding to vWF shows that these a

30 The platelet glycoprotein Ib (GpIb) complex is composed of four polyp

31 The glycoprotein Ib (GPIb) complex is composed of GPIb alpha

32 The expression and function of a glycoprotein Ib (GPIb) complex on human umbilical vein e

33 ultrastructural studies have suggested that Glycoprotein Ib (GPIb) has a different distribution on e

34 munosorbent assay (ELISA)-based assay of VWF-glycoprotein Ib (GPIb) interactions using a gain-of-func

35 of vascular damage through interaction with glycoprotein Ib (GPIb) of the platelet GPIb/IX complex.

36 An aberrant platelet immunorelated glycoprotein Ib (GPIb) receptor expressed by human tumor

37 Glycoprotein Ib (GPIb) shedding, exposure of P-selectin,

38 s is mediated by interaction of the platelet glycoprotein Ib (GPIb) surface receptor and its arterial

39 Platelets use receptor glycoprotein Ib (GPIb), specifically its alpha subunit (

40 latelet adhesion through binding to platelet glycoprotein Ib (GPIb).

41 eractions with the platelet receptor complex glycoprotein Ib (GPIb).

42 its primary ligand on the platelet surface, glycoprotein Ib (GpIb).

43 orption with mouse antihuman CD42b [platelet glycoprotein Ib (GPIb)] mAb, had sizes and cargo protein

44 Rapid chilling causes glycoprotein-Ib (GPIb) receptors to cluster on blood pla

45 hat inhibits binding of thrombin to platelet glycoprotein Ib inhibits secretory responses to thrombin

46 ezers to study the unbinding forces from the glycoprotein Ib-IX (GP Ib-IX) complex of plasma VWF, ULV

47 ebrand factor (VWF) to the platelet membrane glycoprotein Ib-IX (GPIb-IX) results in platelet activat

48 by VWF binding to its receptor, the platelet glycoprotein Ib-IX (GPIb-IX), and p38 inhibitors diminis

49 et receptor for von Willebrand factor (vWF), glycoprotein Ib-IX (GPIb-IX), mediates initial platelet

50 atelet von Willebrand factor (vWF) receptor, glycoprotein Ib-IX (GPIb-IX), mediates platelet adhesion

51 ctor (vWF) binding to its platelet receptor, glycoprotein Ib-IX (GPIb-IX), via the protein kinase G (

52 A limited number of mutations within the glycoprotein Ib-IX complex have been described that perm

53 ly dependent on integrin alpha6beta1 and the glycoprotein Ib-IX complex, which binds to plasmatic von

54 mulatory role in platelet activation via the glycoprotein Ib-IX pathway.

55 The platelet glycoprotein Ib-IX receptor binds surface-bound von Will

56 (vWF)-dependent recruitment of the platelet glycoprotein Ib-IX receptor complex and collagen interac

57 factor (VWF) axis caused by mutations in the glycoprotein Ib-IX receptor that lead to an increased af

58 topes for drug-dependent antibody binding on glycoprotein Ib-IX, glycoprotein IIb-IIIa, and platelet-

59 et receptor for von Willebrand factor (vWF), glycoprotein Ib-IX, integrin alphaIIb, and mutants of be

60 The glycoprotein Ib-IX-V (GP Ib-IX-V) complex mediates plate

61 Glycoprotein Ib-IX-V (GPIb-IX-V) mediates platelet tethe

62 due to absent or decreased expression of the glycoprotein Ib-IX-V (GpIb-IX-V) receptor complex on the

63 een subendothelial collagen and the platelet glycoprotein Ib-IX-V complex (GPIb).

64 he von Willebrand Factor (VWF) receptor, the glycoprotein Ib-IX-V complex (GPIb-IX), but not by GPIb-

65 The platelet glycoprotein Ib-IX-V complex (GPIb-IX-IV) is the recepto

66 factor (vWF) that enhance its binding to the glycoprotein Ib-IX-V complex on platelets.

67 The platelet glycoprotein Ib-IX-V complex plays critical roles in adh

68 The platelet glycoprotein Ib-IX-V complex plays crucial roles in both

69 , the ligand binding subunit of the platelet glycoprotein Ib-IX-V complex, is sulfated on three tyros

70 The platelet adhesion receptor, the glycoprotein Ib-IX-V complex, not only mediates platelet

71 thin the glycoprotein Ibalpha subunit of the glycoprotein Ib-IX-V complex, we utilized mocarhagin, a

72 pathways and regulatory mechanisms involving glycoprotein Ib-IX-V function.

73 intracellular signal-mediated regulation of glycoprotein Ib-IX-V receptor function that requires the

74 telet activation occurs after binding of the glycoprotein Ib-IX-V receptor to von Willebrand factor i

75 in understanding the mechanism(s) regulating glycoprotein Ib-IX-V should help develop inhibitors and

76 n of intracellular molecules and pathways in glycoprotein Ib-IX-V signaling has implications in the d

77 Glycoprotein Ib-IX-V signaling is mediated by the Src fa

78 nd for the use of existing drugs that affect glycoprotein Ib-IX-V signaling.

79 his process requires the binding of platelet glycoprotein Ib-IX-V to the A1 domain of VWF monomeric s

80 platelet rolling via interaction of platelet glycoprotein Ib-IX-V with endothelial-released von Wille

81 The interaction of glycoprotein Ib-IX-V with its ligand, von Willebrand fac

82 -VWD) is a bleeding disorder of the platelet glycoprotein Ib-IX/von Willebrand factor (VWF) axis caus

83 he antibody was shown to be specific for the glycoprotein Ib/IX complex (GPIb/IX).

84 to thrombin but not to TRAP, so occupancy of glycoprotein Ib per se accounts for only part of the att

85 A2, and A3 domains in vWF mediate binding to glycoprotein Ib, ristocetin, botrocetin, collagen, sulph

86 Platelet glycoprotein Ib, T-cell receptor, and integrins are used